Sclerosis multiplex (SM): vizsgálatok itt: Németország
39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- No phaseTaking peopleA Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
- Where
- Aachen, Amberg, Arnsdorf, Aschaffenburg, Bad Soden, Bamberg, Berg, Berlin, Bochum, Bogen, Buchholz, Celle, Chemnitz, Cologne, Dortmund, Düsseldorf, Eltville, Erbach/Odenwald, Erlangen, Essen, Forchheim, Frankfurt, Freiburg im Breisgau, Füssen, Giessen, Gladenbach, Günzburg, Halle, Hamburg, Hanover, Hennigsdorf, Herford, Hettingen, Ibbenbueren, Isselburg, Jena, Kiel, Leipzig, Lübeck, Magdeburg, Mannheim, Marburg, Meerbusch, Minden, München, Münster, Neuburg am Inn, Neuruppin, Neu-Ulm, Nuremberg, Öhringen, Osnabrück, Pforzheim, Quakenbrück, Regensburg, Remscheid, Rülzheim, Schwetzingen, Siegen, Singen, Sinsheim, Steglitz, Stuttgart, Sundern, Tübingen, Ulm, Unterhaching, Weil der Stadt, Wolfratshausen, Zwickau
- Életkor
- 18 év and over
- People
- 842 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06780150 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Bad Homburg, Bayreuth, Boeblingen, Dresden, Essen, Hamburg, Leipzig, Mainz, Neuburgan der Donau, Trier, Ulm
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Bad Homburg, Bayreuth, Erbach, Essen, Greifswald, Jena, Leipzig, Mainz, Muenster, Potsdam, Regensburg, Trier, Ulm, Wiesbaden
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 2. fázisTaking peopleStudy to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
- Where
- Bielefeld, Bochum, Dresden, Jena, Kassel, Muenster, Siegen, Wuerzburg
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Celgene Corp.
See details and how to join2024-517745-14-00 · EU 2024-517745-14-00 - 3. fázisTaking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Bochum, Dresden, Duesseldorf, Leipzig, Ulm
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - 3. fázisTaking peopleAn Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
- Where
- Bremen, Ulm, Wiesbaden
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06675955 · EU 2023-507633-21-01 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Where
- Bielefeld, Bochum, Dresden, Essen, Jena, Kassel, Meisenheim, Münster, Siegen, Würzburg
- Életkor
- 18 év to 70 év
- People
- 200 worldwide
- Run by
- Celgene
See details and how to joinNCT06782490 - No phaseNot yet taking people in NémetországEvaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
- Where
- Ulm
- Életkor
- 18 év to 70 év
- People
- 100 worldwide
- Run by
- Otto Bock Healthcare Products GmbH
See details and how to joinNCT07897760 - 3. fázisTaking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Berlin, Bochum, Erbach, Essen, Greifswald, Heidelberg, Marburg, Muenster, Regensburg, Ulm
- Életkor
- 40 év to 70 év
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - 2. fázisTaking peopleMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
- Where
- Cologne, Dresden, Duesseldorf, Erbach, Greifswald, Hamburg
- Életkor
- 18 év to 64 év
- People
- 230 worldwide
- Run by
- Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00 - 3. fázisTaking peopleA Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
- Where
- Dresden, Leipzig, Unterhaching
- Életkor
- 18 év to 64 év
- People
- 125 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00 - 2. fázisNot yet taking people in NémetországA Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
- Where
- Datteln, Dresden
- Életkor
- 10 év to 17 év
- People
- 25 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07503340 · EU 2025-524164-37-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Cottbus, Erbach im Odenwald, Erfurt, Freiburg im Breisgau, Giessen, Greifswald, Halle, Heidelberg, Ibbenbueren, Itzehoe, Jena, Leipzig, Mannheim, Munich, Tübingen, Ulm, Unterhaching, Wiesbaden
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Berlin, Bielefeld, Bochum, Boeblingen, Dresden, Duesseldorf, Erbach, Essen, Giessen, Jena, Leipzig, Muenster, Ulm
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - 2. fázisTaking peopleA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- Where
- Berlin, Bochum, Bonn, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Leipzig, Mannheim, Muenster, Munich, Tuebingen, Ulm
- Életkor
- 18 év to 60 év
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00 - 3. fázisTaking peopleEfficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Where
- Bochum, Freiburg im Breisgau, Goettingen
- Életkor
- Up to 17 év
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00 - 1/2. fázisTaking peopleMB-CART2019.1 in refractory MS
- Where
- Berlin, Hamburg
- Életkor
- 18 év and over
- People
- 25
- Run by
- Miltenyi Biomedicine GmbH
See details and how to join2024-517601-82-00 · EU 2024-517601-82-00 - No phaseCsak meghívásosMS-Related Disability Worsening and Thalamic Volume Loss
- Where
- Dresden, Multiple Locations
- Életkor
- 18 év to 55 év
- People
- 2400
- Run by
- Jung Diagnostics GmbH
See details and how to joinNCT07753928 - 1. fázisTaking peopleAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis
- Where
- Leipzig, Magdeburg, Würzburg
- Életkor
- 18 év to 60 év
- People
- 24 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07224373 - 1/2. fázisNot yet taking people in NémetországAn open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
- Where
- Tuebingen
- Életkor
- 18 év and over
- People
- 36
- Run by
- Universitaetsklinikum Tuebingen AöR
See details and how to join2024-519491-60-00 · EU 2024-519491-60-00 - No phaseTaking peoplePregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- Where
- Bochum
- People
- 908 worldwide
- Run by
- Biogen
See details and how to joinNCT05658497 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Cottbus, Erbach, Erfurt, Freiburg im Breisgau, Giessen, Greifswald, Halle (saale), Heidelberg, Ibbenbueren, Itzehoe, Jena, Leipzig, Mannheim, Munich, Tuebingen, Ulm, Unterhaching, Wiesbaden, Wuerzburg
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00 - No phaseTaking peopleA NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- Where
- Aalen, Albstadt, Altenburg, Altenholz, Altmark, Alzey, Bad Homburg, Bamberg, Bayreuth, Bergneustadt, Berlin, Böblingen, Bochum, Bogen, Bonn, Braunschweig, Bremen, Chemnitz, Coburg, Cologne, Crailsheim, Dessau, Dillingen an der Donau, Dillingen Saar, Dortmund, Dresden, Duisburg, Düsseldorf, Eisleben Lutherstadt, Eltville, Erbach im Odenwald, Erfurt, Erlangen, Essen, Falkensee, Frankfurt am Main, Fulda, Gelsenkirchen, Giessen, Gladenbach, Görlitz, Hagen, Halle, Hamburg, Hanover, Hettingen, Höxter, Ingelheim, Itzehoe, Jena, Kaiserslautern, Karlsruhe, Leipzig, Lünen, Magdeburg, Mannheim, Marburg, Meerbusch, Merzig, Mettmann, Minden, Montabaur, Mühlhausen, Mülheim, München, Munich, Münster, Nagold, Neuburg A.d. Donau, Neuruppin, Nuremberg, Oer-Erkenschwick, Oldenburg, Osnabrück, Pforzheim, Potsdam, Regensburg, Remscheid, Rostock, Rüdersdorf, Rülzheim, Saarlouis, Salzatal, Schiltach, Schneverdingen, Schwäbisch Hall, Schwetzingen, Siegen, Sinsheim, Stadtroda, Stuttgart, Tirschenreuth, Trier, Tübingen, Unterhaching, Untermeitingen, Velbert, Weil der Stadt, Wildeshausen, Wolfratshausen
- Életkor
- 18 év to 100 év
- People
- 800
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05344469 - 1. fázisNot yet taking people in NémetországImmune Cell Therapy for People with Early, Active Multiple Sclerosis
- Where
- Hanover
- Életkor
- 18 év and over
- People
- 10
- Run by
- Medizinische Hochschule Hannover
See details and how to join2025-522409-39-00 · EU 2025-522409-39-00 - 1/2. fázisTaking peopleMB-CART2019.1 in Refractory Multiple Sclerosis
- Where
- Berlin
- Életkor
- 18 év to 55 év
- People
- 26
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT07178431